In spite of these disadvantages, targeting CD46 instead of CAR with a chimeric HAdV-C5 which contained the fiber of HAdV-B35 enhanced killing of CD46 expressing colon cancer cells [45] and bladder cancer cells [42], both in vitro and in in vivo mouse models. The gene discussed is CD46; the disease is urinary bladder cancer.